

LENZ & STAEHELIN ADVISES ASCENEURON ON ITS AGREEMENT WITH FERRER

Posted on 28 February 2023



Categories: [Corporate](#), [IP](#)

Tags: [Anne-Laure Laplace](#), [Asceneuron](#), [Federico Trabaldo Togna](#), [Lenz & Staehelin](#), [Sevan Antreasyan](#), [Slider](#)



Spanish pharmaceutical company **Ferrer** and Swiss clinical stage biotechnology company **Asceneuron** have announced the signing of a licensing agreement in which Ferrer obtains the exclusive worldwide rights to develop and commercialize **ASNgo** in progressive supranuclear palsy (PSP), an orphan neurological disease with a high unmet medical need.

This agreement underscores the commitments both companies have undertaken to improve the lives of patients with a rare disease, such as Progressive Supranuclear Palsy (PSP). The terms of the agreement include an upfront fee and multiple development, regulatory and commercial milestone payments. Asceneuron is also eligible to receive tiered double-digit royalties on worldwide net sales of ASNgo.

[Lenz & Staehelin](#) advised Asceneuron in this transaction. The team was led by partner **Sevan Antreasyan** (IP, commercial and contracts, pictured) and included **Anne-Laure Laplace** (IP, commercial and contracts) and **Federico Trabaldo Togna** (corporate and m&a).